Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.96 -0.81%

-$0.04 today

Market cap
$318.00M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.45M

Average 0.34M

Returns on capital

Atea Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-57.5%

avg -20.9%

ROIC

-63.0%

avg -30.4%

ROA

-50.2%

avg -24.9%

Analysis

ROA is currently the strongest return metric at -50.2% versus its period average of -24.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jean-Pierre Sommadossi

Founder, Chairman, Chief Executive Officer & PresidentUSD 1.13M700<0.01%

Janet J. Hammond

Chief Development OfficerUSD 870.79K66——

Andrea J. Corcoran

Chief Financial Officer, Executive Vice President of Legal & SecretaryUSD 810.82K64——

Maria Arantxa Horga

Chief Medical OfficerUSD 747.1K580<0.01%

John F. Vavricka

Chief Commercial OfficerUSD 634.44K63——

Wayne Foster

Executive Vice President of Finance & Chief Accounting OfficerUSD 580.46K570<0.01%

Adel Moussa

Executive Vice President of Chemistry————

Keith Pietropaolo

Executive Vice President of Clinical Sciences & Project Management————

Xiao-Jian Zhou

Executive Vice President of Early Stage Development————

Jonae R. Barnes

Senior Vice President of Investor Relations & Corporate Communications————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$25,446.15

Sells

0

$0.00

Net Transaction Value

+$25,446.15

Net buying

Most Active

Murphy Polly A.

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 18, 26

Murphy Polly A.

Direct

Buy$25.4K

Summary

Insiders reported 1 buys worth $25,446.15 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $25,446.15. Murphy Polly A. was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Atea Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AVIR's management, answered from reported figures.

Who manages AVIR?

Atea Pharmaceuticals, Inc. (AVIR) lists 10 active executives. The top listed executive is Janet J. Hammond, Chief Development Officer.

Are AVIR insiders buying or selling?

Recent insider activity shows net buying of $20.66M.